Urolithin A is a postbiotic compound produced when gut bacteria metabolize ellagitannins found in pomegranates, walnuts, and certain berries. It has attracted scientific attention for its ability to stimulate mitophagy: the process by which cells clear out damaged mitochondria and replace them with healthier ones. This mitochondrial renewal is thought to underlie some of the performance and longevity-related effects observed in early human studies.
For most healthy adults, urolithin A appears to be well tolerated, and early clinical data have not flagged serious safety signals. However, the research base is still young, and specific populations have not been studied thoroughly enough to assume the same safety profile applies universally. This article outlines the groups for whom extra caution, and a conversation with a healthcare provider, is warranted before starting urolithin A supplementation.
Key Takeaways
- Pregnant and breastfeeding women should avoid supplemental urolithin A due to the complete absence of safety data for these groups.
- People on immunosuppressant drugs should consult their prescribing physician before use, as immune-modulating effects have not been studied in this context.
- Children and adolescents have not been studied in any urolithin A trial and should not use supplements without explicit medical guidance.
- Individuals with liver or kidney impairment lack pharmacokinetic data to confirm safe clearance of the compound.
- Urolithin A production varies by gut metabotype, and people with significantly disrupted gut microbiomes may have unpredictable responses to ellagitannin-rich foods, though supplemental forms bypass this conversion step.
Pregnant and Breastfeeding Women
There are currently no published clinical trials evaluating urolithin A supplementation specifically in pregnant or breastfeeding women. This absence of data is itself a reason for caution: it is not the same as evidence of harm, but it means there is no established basis for concluding that supplementation is safe during these periods.
Urolithin A trials enrolled mostly healthy adults, and several groups were never tested
Healthy adults
Trials enrolled 88 healthy middle-aged adults and 66 adults aged 65 to 90. The older trial was all White and from Seattle, so its authors call it preliminary.
Heart failure
One crossover trial in 10 patients with heart failure found no significant change in heart function.
Kidney and liver checks
In 50 healthy middle-aged adults, 28 days of urolithin A did not significantly change kidney function or liver enzymes.
Breastfeeding
A pilot of 10 breast-feeding mothers drinking pomegranate juice found urolithin A-glucuronide in breast milk and infant urine. No supplement was tested.
Other groups
The evidence reviewed here has no trial in pregnancy, children, or people on immunosuppressants. No data is not evidence of safety.
If you are in a group that was never studied, treat urolithin A supplements with caution and ask a clinician first.
Cards show who the evidence covers; the last card is an absence of trials, not a finding of harm. Source: Singh et al., Cell Reports Medicine 2022; Liu et al., JAMA Network Open 2022; Jamialahmadi et al., Reviews on Recent Clinical Trials 2024; Denk et al., Nature Aging 2025; Henning et al., Food & Function 2022.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
What research does show is that the gut microbiome changes substantially during and after pregnancy, which affects how ellagitannins are converted into urolithin A in the first place. Studies examining urolithin metabotypes, the distinct patterns of urolithin production based on an individual’s gut bacteria, found meaningful variation in gut microbiota composition during the first year postpartum, with implications for how the body processes these compounds [1]. This variability means that postpartum women may produce urolithin A very differently than the average adult studied in trials.
Until dedicated safety data exist for pregnant and lactating individuals, the prudent approach is to avoid supplemental urolithin A during pregnancy and while breastfeeding, and to rely on food sources of ellagitannins only as part of a varied diet.
One small pilot of 10 breast-feeding mothers drinking pomegranate juice daily found urolithin A-glucuronide in breast milk and in the infants’ urine, so food-derived urolithin A can reach infants. That pilot did not test supplements or infant outcomes [8].
People Taking Immunosuppressant Medications
Urolithin A has been shown in preclinical research to modulate immune signaling pathways, including effects on inflammatory cytokine production. While this is often framed as a benefit in the context of aging-related inflammation, it also raises a theoretical concern for people whose immune systems are deliberately suppressed, such as organ transplant recipients taking calcineurin inhibitors or individuals managing autoimmune conditions with biologics or corticosteroids.
Research note: Metabotype assignment can change within a person and depends on how much precursor was eaten, classification thresholds and sampling matrix, so a single test may misclassify someone [10].
There are no published human studies examining the interaction between urolithin A and immunosuppressant drugs. The concern is not that an interaction has been demonstrated, but that it has not been sufficiently ruled out. Anyone in this category should speak with their prescribing physician before adding urolithin A, as even modest immune modulation could potentially interfere with graft tolerance or disease management.
Children and Adolescents
Published urolithin A clinical trials have enrolled adults, typically middle-aged or older. No trials have assessed safety or pharmacokinetics in children or teenagers. The effects of supplementing these pathways during growth and development are entirely unknown.
Children and adolescents eating whole foods that naturally contain ellagitannins (pomegranate, raspberries, walnuts) are not expected to make much urolithin A from typical dietary amounts, since conversion from whole foods is modest and varies widely between people [2]. Concentrated supplements are a different matter and should not be given to minors without explicit medical guidance.
People With Significant Gut Microbiome Disruption
One of the more underappreciated aspects of urolithin A research is that not everyone produces it equally. Human populations fall into distinct urolithin metabotypes: some people produce urolithin A efficiently, others produce a different spectrum of urolithins, and a meaningful proportion produce very little regardless of ellagitannin intake. These metabotypes are determined by gut microbiome composition [1].
People who have recently completed a course of broad-spectrum antibiotics, those with inflammatory bowel disease, or individuals who have had significant portions of the colon removed may have substantially altered microbiome profiles. For supplemental urolithin A, which bypasses gut conversion entirely, this does not directly affect how the compound is absorbed. However, it is worth understanding that the metabotype variation documented in research suggests that gut health and urolithin metabolism are deeply connected, and individuals with severely compromised gut function should discuss supplementation with a gastroenterologist.
Separately, urolithin A supplements sometimes contain excipients or are formulated in ways that could aggravate sensitive digestive conditions. Anyone with active gastrointestinal disease should review the full ingredient list carefully.
People With Liver or Kidney Conditions
Most circulating urolithin A is in a conjugated form, a glucuronide, rather than as the parent compound [3]. Clinical trials to date have not enrolled participants with significant hepatic or renal impairment, which means there is no pharmacokinetic data describing how the compound accumulates or clears in people with compromised organ function.
This gap is not unique to urolithin A: it applies to most newer supplements. However, it is a practical reason for individuals with chronic kidney disease, cirrhosis, or other conditions affecting liver or kidney clearance to consult a physician before use. The possibility of altered drug-like kinetics in these populations cannot be dismissed without specific study data.
In a 28-day trial of 50 healthy adults, no significant changes were seen in kidney function parameters or liver enzymes, but that trial did not include people with liver or kidney disease [9].
People on Multiple Medications or With Complex Health Conditions
Urolithin A acts on multiple cellular pathways, including mitophagy, NF-κB inflammatory signaling, mostly in cell and animal work; a systematic review of human studies found no effect on mitochondrial biogenesis. These effects have not been shown to benefit healthy populations [4][5], anyone managing a complex chronic condition (heart failure, cancer, neurodegenerative disease) should be cautious about adding any supplement that influences fundamental cellular processes without medical oversight.
The concern is not that urolithin A is known to cause drug interactions, but that formal interaction studies have not been done. Certain chemotherapy regimens, for example, deliberately target rapidly dividing cells or exploit mitochondrial vulnerabilities; supplementing mitochondrial renewal pathways during active cancer treatment could theoretically work at cross purposes with the treatment, even if this has not been formally studied. When in doubt, transparency with your oncologist or specialist is the right approach.
A Note on the Evidence
Urolithin A research in humans is still in early stages, and the populations studied in clinical trials have been largely healthy adults without complex medical conditions. This article is for informational purposes only and does not constitute medical advice. Anyone who is pregnant, breastfeeding, managing a chronic illness, or taking prescription medications should consult a qualified healthcare provider before starting urolithin A supplementation.
Frequently Asked Questions
Is urolithin A safe for most people?
For healthy middle-aged and older adults, published clinical trials have not raised major safety concerns at doses studied (500 mg and 1,000 mg per day in the main trials) [6][7]. However, the research base is still relatively small and does not cover all populations. Anyone outside the groups studied in trials should exercise appropriate caution and speak with a doctor if they have underlying health conditions.
Can pregnant women eat pomegranates and foods rich in ellagitannins?
Whole foods containing ellagitannins (such as pomegranates, raspberries, and walnuts) are generally considered safe as part of a normal diet during pregnancy. The concern with caution applies to concentrated supplemental urolithin A, not typical dietary intake of fruits and nuts. Always discuss significant dietary changes during pregnancy with a midwife or obstetrician.
Why does gut microbiome health matter for urolithin A?
When urolithin A comes from food rather than supplements, it must first be produced by gut bacteria that convert ellagitannins. Research has shown that people fall into distinct urolithin metabotypes based on their microbiome composition, and these patterns can shift significantly during events like the postpartum period [1]. This means that food-derived urolithin A levels vary widely between individuals depending on their gut bacteria.
Does urolithin A interact with medications?
Formal drug interaction studies for urolithin A are not yet published. Because it influences immune and inflammatory pathways, a theoretical concern exists for people on immunosuppressants or certain other drugs. There is no known confirmed interaction at this time, but the absence of data means caution is warranted, particularly for anyone on multiple prescription medications.
What is mitophagy and why does it matter for understanding urolithin A?
Mitophagy is the cellular recycling process that identifies and removes damaged mitochondria so they can be replaced by healthy ones. As cells age, this process becomes less efficient, leading to accumulation of dysfunctional mitochondria that impair energy production and increase cellular stress. Urolithin A is thought to stimulate this cleanup process, which is the proposed mechanism behind its potential effects on muscle function and cellular resilience.
Should people with autoimmune conditions avoid urolithin A?
There is no clinical evidence showing that urolithin A is harmful for autoimmune conditions, but its immune-modulating properties have not been tested in this population. People managing autoimmune diseases, particularly those on disease-modifying drugs, should consult their rheumatologist or specialist before adding urolithin A supplementation, as even theoretical interactions with their treatment are worth discussing.
References
- Cortés-Martín A et al. Urolithin Metabotypes can Anticipate the Different Restoration of the Gut Microbiota and Anthropometric Profiles during the First Year Postpartum. Nutrients (2019). PMID 31484413
- Begoña Cerdá et al. Metabolism of Antioxidant and Chemopreventive Ellagitannins from Strawberries, Raspberries, Walnuts, and Oak-Aged Wine in Humans: Identification of Biomarkers and Individual Variability. Journal of Agricultural and Food Chemistry (2004). PMID 15656654
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Chang Liu et al. Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction. Frontiers in Endocrinology (2026). PMID 41884209
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Henning SM et al. Pomegranate juice alters the microbiota in breast milk and infant stool: a pilot study. Food & function (2022). PMID 35510588
- Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
- Lingmin Hu et al. Urolithins in clinical translation: from gut microbial metabolites to precision interventions. Frontiers in Nutrition (2026). PMID 42626640
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.